Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + methotrexate + procarbazine + vincristine
- Development stage
- Unknown
- Lead developer
- Biogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Rituximab + methotrexate + procarbazine + vincristine (R-MPV) is a multi-drug chemoimmunotherapy regimen used as induction therapy for newly diagnosed primary central nervous system lymphoma (PCNSL). The regimen consists of rituximab (a CD20-directed monoclonal antibody), methotrexate (an antimetabolite), procarbazine (an alkylating agent), and vincristine (a vinca alkaloid). It is typically administered in 14-day cycles for 5 to 7 cycles, and is often followed by consolidation therapies such as reduced-dose whole-brain radiotherapy (WBRT), cytarabine, or high-dose chemotherapy with autologous stem-cell transplantation (HDC-ASCT).
- Other names
- R-MPVR-MPV regimenR-MVPR-MVP regimen
02
Targets
CD20 (B-lymphocyte antigen CD20)DNADHFR (Dihydrofolate reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on rituximab + methotrexate + procarbazine + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + methotrexate + procarbazine + vincristine.